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Abstract
Background: KRAS mutations occur in 35–45% of metastatic colorectal cancers (mCRC) and preclude responsiveness to
EGFR-targeted therapy with cetuximab or panitumumab. However, less than 20% patients displaying wild-type KRAS tumors
achieve objective response. Alterations in other effectors downstream of the EGFR, such as BRAF, and deregulation of the
PIK3CA/PTEN pathway have independently been found to give rise to resistance. We present a comprehensive analysis of
KRAS, BRAF, PIK3CA mutations, and PTEN expression in mCRC patients treated with cetuximab or panitumumab, with the
aim of clarifying the relative contribution of these molecular alterations to resistance.
Methodology/Principal Findings: We retrospectively analyzed objective tumor response, progression-free (PFS) and overall
survival (OS) together with the mutational status of KRAS, BRAF, PIK3CA and expression of PTEN in 132 tumors from
cetuximab or panitumumab treated mCRC patients. Among the 106 non-responsive patients, 74 (70%) had tumors with at
least one molecular alteration in the four markers. The probability of response was 51% (22/43) among patients with no
alterations, 4% (2/47) among patients with 1 alteration, and 0% (0/24) for patients with $2 alterations (p,0.0001).
Accordingly, PFS and OS were increasingly worse for patients with tumors harboring none, 1, or $2 molecular alteration(s)
(p,0.001).
Conclusions/Significance: When expression of PTEN and mutations of KRAS, BRAF and PIK3CA are concomitantly
ascertained, up to 70% of mCRC patients unlikely to respond to anti-EGFR therapies can be identified. We propose to define
as ‘quadruple negative’, the CRCs lacking alterations in KRAS, BRAF, PTEN and PIK3CA. Comprehensive molecular dissection of
the EGFR signaling pathways should be considered to select mCRC patients for cetuximab- or panitumumab-based
therapies.
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Introduction
Colorectal cancer (CRC) is the third cause of cancer-related
death in the western world [1]. Despite improvements in the
therapeutic armamentarium for metastatic CRC (mCRC), the 5-
year overall survival (OS) remains poor, with a median survival of
18 to 21 months [2]. Additional drugs, as well as further insights
about the mechanisms of resistance, are needed to improve clinical
outcome. Treatment options for mCRC nowadays include the
chimeric IgG1 monoclonal antibody (moAb) cetuximab and the
human IgG2moAb panitumumab [3,4]. Both molecules bind to the
Epidermal Growth Factor Receptor (EGFR), leading to inhibition
of its downstream signaling, providing a meaningful clinical benefit.
Objective response rates in unselected populations of mCRC,
however, are limited to 8–12% for these agents when used as
monotherapy in first [5] and subsequent lines of treatment [4,6,7].
We and others have previously shown that somatic KRAS
mutations (a key effector of the EGFR initiated signaling) can
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7287
independently impair the efficacy of panitumumab or cetuximab
[8–10]. This led the U.S. and European health authorities to
restrict the use of these agents for patients with wild-type KRAS
mCRC only [11–13]. Although this decision is expected to
ameliorate the therapeutic index in this selected population, the
objective response rate is still very limited. In fact, it is restricted to
17% (vs 0% in KRAS mutated) for panitumumab monotherapy
[10], to 12.8% (vs 1.2% in KRAS mutated) for cetuximab
monotherapy [14] and to 59–61% (vs 36–33% in KRAS mutated)
for cetuximab plus either irinotecan- or oxaliplatin-based chemo-
therapy, respectively [15,16]. These findings clearly suggest that
other factors, such as alterations in other EGFR effectors,
including members of the RAS-MAPK or PI3K pathways could
drive resistance to anti-EGFR therapy.
BRAF is the principal downstream effector of KRAS [17,18]
and its oncogenic V600E mutation is mutually exclusive with
KRAS mutations in CRCs [19]. We and others have recently
demonstrated that the V600E mutation can also preclude
responsiveness to panitumumab or cetuximab in mCRC patients
and cellular models of CRC [20]. The PIK3CA gene is mutated in
approximately 20% of CRCs [21]. PIK3CA mutations occurring in
the ‘hotspots’ located in exon 9 (E542K, E545K) and exon 20
(H1047R) are oncogenic in CRC cellular models [22,23]. The
PIK3CA gene encodes for a lipid kinase that regulates, alongside
with KRAS, signaling pathways downstream of the EGFR. PI3K
initiated signaling is normally inhibited by PTEN (phosphatase
and tensin homologue deleted on chromosome ten). We and
others have previously shown that loss of PTEN expression, which
occurs in 30% of sporadic cases, is associated with lack of response
to cetuximab [24], and that PIK3CA/PTEN deregulation may be a
biomarker of resistance in KRAS wild-type patients [25,26] and
cellular models of CRC [27].
Taken together, data from retrospective analyses show that
BRAF and PIK3CA/PTEN alterations could represent additional
tools for selecting mCRC patients for EGFR-targeted treatment
[20,24–26]. Nevertheless, a clear identification of which biomark-
ers should be employed together with KRAS in the clinical setting
remains to be defined. This is because in these retrospective
analyses: a) different determinants were evaluated in each study;
and b) an overlapping among some of these biomarkers may occur
in individual patients. In the present study, we performed the first
comprehensive mutational analysis of KRAS, BRAF, and PIK3CA,
alongside with the evaluation of PTEN expression in a cohort of
132 mCRC treated patients.
Results
Distribution and overlap of molecular alterations in
individual tumors
As shown in Figure 1, analysis of tumors from a cohort of 132
patients (for clinico-pathological features, see Table 1) led to the
identification of 104 molecular alterations. Specifically, we
detected 35 KRAS mutations (26.5%), 11 BRAF mutations
(8.3%), 17 PIK3CA mutations (12.3%), and 41 (out of 114
evaluable) loss of PTEN expression (36.0%). Mutations of KRAS
occurred in codon 12 in 24 cases (68.6%) and in codon 13 in 10
cases (28.6%); a double point mutation involving both codons was
detected in one case (2.9%). PIK3CA mutations were found either
in exon 9 (4 cases) or in exon 20 (13 cases). The 11 mutations of
BRAF were all V600E substitutions.
Mutations of KRAS and BRAF occurred in a mutually exclusive
manner, while an overlapping pattern was observed among other
alterations. The most frequent overlapping fingerprints were
Figure 1. Representation of the distribution of molecular
alterations in individual tumors of the 132 patients: mutations
of KRAS and BRAF occurred in a mutually exclusive manner, while
an overlapping pattern was observed between other alterations.
doi:10.1371/journal.pone.0007287.g001
Table 1. Patients’ baseline characteristics.
Number of patients 132
Median age (years) [range] 63.5 [26–85]
Gender (male/female) 86/46
Primary tumour site
Colon 78
Sigma-rectum junction 19
Rectum 31
Other* 4
EGFR targeted therapy
Cetuximab 109
Panitumumab 23
Previous chemotherapy (%)
Irinotecan based 117 (88.6%)
Fluoropyrimidine/capecitabine based 115 (87.1%)
Oxaliplatin based 105 (79.5%)
No. of previous cancer treatments for advanced disease prior anti-EGFR
moAbs (%)
None 13 (9.8%)
One 19 (14.4%)
Two 65 (49.2%)
Three 29 (22.0%)
More than three 6 (4.5%)
Cutaneous toxicity (%)
0 21 (15.9%)
1 67 (50.7%)
2–3 37 (28.0%)
Unknown 7 (5.3%)
*Other: in two cases, primary tumor site was small bowel, in one case
duodenum and in one case primary tumor sites were multiple (colon and
rectum).
doi:10.1371/journal.pone.0007287.t001
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PTEN loss and KRAS mutations (co-occurring in 13 patients), and
BRAF and PIK3CA mutations (in 7 patients) (Figure 1).
Association of clinical variables and objective tumor
response
Among clinical variables (see Table 1), only cutaneous toxicity
was associated with objective response (Wald’s test: p = 0.002;
direction of response = 0-1-$2). Other clinical variables including
gender, site of primary tumor (colon, sigmoid-rectum junction,
rectum, other sites), and age were not significantly associated with
objective tumor response (p = 0.491, 0.490 and 0.904, respectively;
p values were obtained by Fisher’s exact test for site and gender
and by Wald’s test for age). Since patients selected in this cohort
were treated with mixed lines of previous chemotherapy regimens
(although the vast majority received 2–3 previous lines of
treatment, see Table 1), we also studied the association between
the number of previous chemotherapy lines and objective tumor
response, showing that this variable did not exert any effect
(Wald’s test: p = 0.536).
Multivariate analyses of molecular alterations and
objective response
Multivariate analysis including all four molecular alterations
(adjusted by cutaneous toxicity and number of previous chemo-
therapy lines) showed that only KRAS mutations and loss of PTEN
expression were independently associated with lack of objective
response (p = 0.001 and ,0.001, respectively) (Table 2). Impor-
tantly, the Bayesian informative criterion according to Schwarz
suggested that a model including KRAS mutations and loss of
PTEN expression was overall the best strategy in identifying non-
responsive patients in our cohort.
Multivariate analyses of molecular alterations and
survival
The multivariate Cox analysis for OS confirmed that the role of
KRAS mutations and loss of PTEN was significant in conferring
worse clinical outcome (HR=1.72, p= 0.043 and HR=0.54,
p = 0.012, respectively), with also BRAF mutations exerting a
detrimental borderline effect (HR=2.31, p= 0.093). As for PFS,
only KRAS mutations were associated with decreased survival
(HR=1.65, p = 0.033), whereas none of the other molecular
alterations was demonstrated to independently affect clinical
outcome (Table 3).
Multivariate analyses of molecular alterations and clinical
outcome in patients with wild-type KRAS mCRC
Our cohort consists of retrospective cases and, for this reason,
also KRASmutated patients were included in the analysis. After the
decision of health authorities to restrict the use of cetuximab and
panitumumab to wild-type KRAS mCRC [11–13,28], this
subgroup has achieved utmost relevance. Accordingly, we focused
our analysis on the effect of BRAF and PIK3CA mutations and loss
of PTEN in the remaining 96 wild-type KRAS patients. At
multivariate analysis, loss of PTEN confirmed a significant
association with lack of response (p,0.001), while BRAF and
PIK3CA were not significant (p = 0.265, 0.075, respectively)
(Table 4).
Survival analyses shown in Table 5 demonstrated that BRAF
mutations (HR=3.75, p= 0.015) and loss of PTEN (HR=0.43,
p = 0.009), but not PIK3CAmutations (HR=1.20, p = 0.672), were
significantly associated with decreased OS, whereas none of these
alterations was significantly associated with PFS.
Effect of the number of molecular alterations on clinical
outcome
In light of the occurrence of multiple molecular alterations
within the same tumor, we investigated our cohort by separating
patients according to the actual number of molecular abnormal-
ities in the same tumor, i.e., none vs 1 vs $2 alterations. Because
the molecular status of one marker among PTEN, PIK3CA and
BRAF was undetermined in 18 tumors, we decided to perform this
analysis in the remaining 114 patients.
Table 2. Multivariate analysis of objective response done
with exact logistic regression in the cohort of 132 patients
evaluated in the study.
Molecular alteration
Odds Ratio
of response CI 95% p value
KRAS Mutant versus wild type 0.06 0.001–0.469 0.001
BRAF Mutant versus wild type 0.32 0.000–4.175 0.379
PIK3CA Mutant versus wild type 0.19 0.000–1.701 0.146
PTEN normal versus loss 23.89 3.136–997.754 ,0.001
Odds ratio values are adjusted by score of cutaneous toxicity and number of
previous chemotherapy lines.
doi:10.1371/journal.pone.0007287.t002
Table 3. Multivariate analysis of survival done with exact
logistic regression in the cohort of 132 patients evaluated in
the study.
Molecular
alteration
PFS Hazard
Ratio (CI 95%)
p
value
OS Hazard
Ratio (CI 95%)
p
value
KRAS (mutant versus
wild type)
1.65 (1.041–2.601) 0.033 1.72 (1.017–2.903) 0.043
BRAF (mutant versus
wild type)
1.39 (0.521–3.685) 0.513 2.31 (0.867–6.131) 0.093
PIK3CA (mutant versus
wild type)
1.79 (0.801–4.017) 0.156 1.63 (0.815–3.269) 0.166
PTEN (normal versus
loss)
0.77 (0.501–1.167) 0.213 0.54 (0.332–0.874) 0.012
Hazard ratio values are adjusted by score of cutaneous toxicity and number of
previous chemotherapy lines.
PFS: progression-free survival; OS: overall survival.
doi:10.1371/journal.pone.0007287.t003
Table 4. Multivariate analysis of objective response done
with exact logistic regression among KRAS wild-type patients.
Molecular alteration
Odds Ratio
of response CI 95% p value
BRAF mutant versus wild type 0.24 0.000–3.093 0.265
PIK3CA mutant versus wild type 0.14 0.000–1.203 0.075
PTEN normal versus loss 30.46 3.831–1436.461 ,0.001
Odds ratio values are adjusted by score of cutaneous toxicity and number of
previous chemotherapy lines.
doi:10.1371/journal.pone.0007287.t004
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The probability of response was 51.1% (22/43) among patients
with no alterations, 4.2% (2/47) with 1 alteration, and 0% (0/24)
with $2 alterations, and these difference were statistically
significant (p,0.0001 by Fisher’s exact test). Figure 2 shows
distribution of the number of mutations in the cohort and response
to EGFR-targeted therapy according to the number of molecular
abnormalities within individual tumor samples. The detrimental
effect of accumulating alterations was also confirmed by the
logistic model, showing that, on average, an unitary increase in the
number of alteration(s), would mean a decrease in the odds of
response by 96% (odds ratio = 0.04; p,0.00001). Taken together,
these findings mean that a necessary but not sufficient condition to
reach objective response is to have no more than one of the four
molecular alterations. Similarly, survival analyses showed that
patients displayed different PFS and OS depending on the number
of molecular alterations in their tumors. Figures 3 and 4 show
that PFS and OS were increasingly worse for none, 1 or $2
molecular alterations (p = 0.0002 for both PFS and OS; logrank
test). The pairwise tests adjusted for multiple comparisons
documented that a worse clinical outcome was observed for
patients with tumors bearing $2 alterations vs 1 (p = 0.0198 and
0.0213 for PFS and OS, respectively) and $2 vs none (p = 0.0002
for both PFS and OS), but not for patients with 1 alteration vs
none (p= 0.3852 and 0.3807 for PFS and OS, respectively).
Median PFS was 2.8 months (5.0, 2.8 and 1.7 for patients
harboring none, one or $2 alterations, respectively); median OS
was 9.4 months (14.6, 9.3 and 7.3 for patients harboring none, one
or $2 alterations, respectively).
Discussion
Despite the recent recommendation by ASCO [28] and by
health authorities in Europe [11,12] and US [13] of KRAS testing
as a diagnostic prerequisite for EGFR-targeted cetuximab- or
panitumumab-based therapies for mCRC, the response rate to
either of these drugs is limited to less than 20% in wild-type KRAS
patients [10,14]. Recent data indicate that BRAF or PIK3CA
mutations may contribute for additional 20–30% of resistance
[20,25,26]. In addition, also PTEN has been proposed as an
independent predictive factor of cetuximab efficacy [24,25,27].
However, the relative and overall contribution of each of these
molecular alterations to clinical decision making remains unclear.
Furthermore, whether and to what extent the occurrence of
multiple molecular alterations affects clinical response and
patients’ survival is presently unknown. EGFR copy number
assessed by FISH has also been suggested to be predictive of
clinical outcome to EGFR-targeted therapies [29–33]. However,
EGFR FISH for mCRC is undergoing inter-laboratory standard-
ization [30] and to avoid the introduction of confounding elements
we elected not to carry out this analysis. Here, we exploited the
comprehensive molecular analysis of EGFR downstream effectors
to ascertain their role in predicting response/resistance to
cetuximab or panitumumab in mCRC. By the concomitant
assessment of four molecular alterations, we were able to identify
up to 70% of non-responder patients, a result that has never been
achieved before. Notably, only three patients with tumors carrying
a single alteration were in the subgroup of responders, (two
Table 5. Multivariate analysis of survival done with exact
logistic regression among KRAS wild-type patients.
Molecular
alteration
PFS Hazard
Ratio (CI 95%)
p
value
OS Hazard
Ratio (CI 95%)
p
value
BRAF (mutant versus
wild type)
2.03 (0.66–6.28) 0.218 3.75 (1.29–10.90) 0.015
PIK3CA (mutant versus
wild type)
1.45 (0.51–4.14) 0.492 1.20 (0.52–2.78) 0.672
PTEN (normal versus loss) 0.81 (0.47–1.39) 0.439 0.43 (0.22–0.81) 0.009
Hazard ratio values are adjusted by score of cutaneous toxicity and number of
previous chemotherapy lines.
PFS: progression-free survival; OS: overall survival.
doi:10.1371/journal.pone.0007287.t005
Figure 2. Distribution of the number of mutations (table) and response to EGFR-targeted therapy (pie-charts) according to the
number of molecular abnormalities within individual tumor samples.
doi:10.1371/journal.pone.0007287.g002
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Figure 3. Progression-free survival according to the number of molecular abnormalities within individual tumor samples. Data from
the cohort of patients with a known molecular status of all four markers.
doi:10.1371/journal.pone.0007287.g003
Figure 4. Overall survival according to the number of molecular abnormalities within individual tumor samples. Data from the cohort
of patients with a known molecular status of all four markers.
doi:10.1371/journal.pone.0007287.g004
Biomarkers for Anti-EGFR
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patients with KRAS mutations and one patient with loss of PTEN
expression), whereas no others showed any alteration (‘‘quadruple
negative’’ tumors). This suggests that previously reported outliers,
i.e., very uncommon cases of mCRC with KRAS mutations
responding to therapy [9,14,29,34] may be patients harboring only
one of these molecular alterations, thus not concurrently
deregulating both MAPK and PI3K pathways.
Our data indicate that single or multiple mutations of KRAS,
BRAF, or PIK3CA unfavorably affect clinical outcome to
cetuximab- or panitumumab-based therapies; however, the
possibility that these molecular alterations could be negative
prognostic biomarkers independently from targeted therapies
should be taken into account. The RASCAL retrospective study
conducted on 2721 CRC patients indicated that the presence of
KRAS mutations is associated with a 26% increased risk of fatal
outcome [35]. However, conflicting data on the same topic have
been recently published. In a phase III trial reported by Karapetis
et al. [14], clinical benefit in patients with wild-type KRAS mCRC
was found in cetuximab treated patients but not in control patients
treated with best supportive care only, thus indicating that the
benefit was not due to a prognostic effect of KRAS. Moreover,
Roth et al. [Proc Am Soc Clin Oncol Gastrointestinal Cancers
Symposium 206, 2009; Abstr 288] tested the prognostic value per
stage of KRAS and BRAF mutations using CRC tumor samples
from the adjuvant PETACC3 trial, and they found no significant
effects on relapse-free survival for both mutations, neither in stage
II nor in stage III. Studies assessing the impact of other molecular
alterations rather than KRAS mutations are limited. As for the
prognostic role of PIK3CA and BRAF, in a study including 586
patients by Barault et al., decreased rates of 3-year survival were
associated with mutations of at least one gene among KRAS, BRAF
and PIK3CA [36]. A recent report by Tol et al. found that the
presence of the BRAF V600E mutation was a negative prognostic
marker in 516 patients with metastatic colorectal cancer treated
with capecitabine, oxaliplatin, and bevacizumab based regimens
[37]. Finally, Ogino et al. reported that, in a series of 450 patients
with stage I–III CRC who underwent curative surgery, tumor
PIK3CA mutation was associated with shorter cancer-specific
survival. Such adverse effect of PIK3CA mutation on prognosis was
consistent across most strata of clinical and tumoral predictors of
patient outcome. Interestingly, this adverse effect was mainly
limited to patients with KRAS wild-type tumors [38]
In conclusion, we document that concomitant detection of
KRAS, BRAF and PIK3CA mutations and evaluation of loss of
PTEN expression in mCRC patients has remarkable clinical
implications by increasing the ability to predict the outcome to
EGFR-targeted therapies. In light of the nature of our patient
series, the most reliable indicator of the predictive value of
biomarker(s) is objective tumor response. Interpretation of survival
analyses should indeed take into account a possible limitation due
to patients treated with mixed previous line(s) of chemotherapy
including a 10% (13/132) of patients treated with first-line
cetuximab monotherapy. On the other hand, the study of such
patients represents a unique opportunity to ascertain the predictive
value of a given biomarker without the influence of chemotherapy,
either concurrent or previous, as well as of selection exerted by
other treatments. In light of these considerations, we propose here
a new algorithm for deciding the clinical use of EGFR-targeted
monoclonal antibodies that is based on objective response rates
(Figures 5 and 6). This novel approach deserves validation in
prospective studies with cetuximab- or panitumumab-based
therapies in mCRC prior to have an impact as clinical practice-
changing. Importantly, we found that approximately 20% of
mCRC non-responders do not harbor mutations of KRAS, BRAF,
PIK3CA nor loss of PTEN expression and we propose to define
these tumors as ‘‘quadruple negative’’. The lack of response in
quadruple negative patients may be due to multiple reasons
including but not restricted to: a) the limited sensitivity of current
Figure 5. Algorithm of molecular diagnostics based on data discussed in this study for patients with mCRC candidates to
cetuximab- or panitumumab-based therapies. The area marked in grey within the dotted line box describes the hypothesis generated in this
study.
doi:10.1371/journal.pone.0007287.g005
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sequencing methods in detecting point mutations in DNA
extracted from FFPE tumors [39]; b) the oncogenic deregulation
of the same four genes by mechanism other then mutations (such
as amplification as reported for PIK3CA); c) the occurrence of
alterations in other key elements of the EGFR-dependent signal
cascade (such as for example AKT or MAPK); and d) the presence
of genetic alterations in tyrosine kinase receptors other than
EGFR, providing an alternate pathway of survival and/or
proliferation. Further molecular dissections of the EGFR-initiated
oncogenic signaling cascade are likely to be helpful in improving
the tailoring of EGFR targeted therapies. Overall, our results
underscore the relevance of using molecular-based algorithms to
shift the treatment of solid tumors into the era of personalized
cancer medicine.
Materials and Methods
Ethics statement
Samples were collected according to the ethical requirements
and regulations and obtaining written consent as approved by the
review board of the Ospedale Niguarda Ca’ Granda, Milano, Italy
and of the Ospedale San Giovanni, Bellinzona, Switzerland.
Patient population and treatment regimens
We retrospectively analyzed 132 patients with EGFR-positive
mCRC at Ospedale Niguarda Ca’ Granda (Milan, Italy), at the
Oncogenomics Center, Institute for Cancer Research and
Treatment, (Candiolo, Italy), or at the Institute of Pathology
(Locarno, Switzerland). Patients gave informed consent and were
treated with panitumumab- or cetuximab-based regimens at
Ospedale Niguarda Ca’ Granda or at the Oncology Institute of
Southern Switzerland (Bellinzona, Switzerland). Patients were
selected based on evidence that treatment outcome could be
attributable only to administration of panitumumab or cetuximab.
Patients’ clinical characteristics are reported in Table 1. With the
exception of 13 patients who received cetuximab as frontline
monotherapy [5], the others had failed at least one prior
chemotherapy regimen. Twenty-three (17.4%) received panitu-
mumab monotherapy, fifteen (11.4%) patients cetuximab mono-
therapy, and ninety-four (71.2%) cetuximab plus irinotecan-based
chemotherapy. For patients who progressed on irinotecan-based
chemotherapy, cetuximab was administered with irinotecan at the
same dose and schedule to which they were resistant. Treatment
was continued until progressive disease (PD) or toxicity occurred,
as per standard criteria [40].
Clinical evaluation and tumor response criteria
Clinical response was assessed every 6–8 weeks with radiological
examination (CT or MR) according to RECIST criteria.
Objective tumor responses were classified into partial response
(PR), stable disease (SD), and PD. Patients with SD or PD were
also defined as non-responders. Response to therapy was also
evaluated retrospectively by independent radiologists.
Molecular analyses
Formalin-fixed paraffin-embedded (FFPE) tumor blocks were
reviewed for quality and tumor content. A single representative
block, from either the primary tumor or the liver metastasis,
depending on availability, containing at least 70% of malignant
cells, was selected for each case. Genomic DNA was extracted
using the QIAamp Mini kit (Qiagen, Chatsworth, CA, USA)
according to the manufacturer’s instructions. Molecular analyses
were performed on tissue sample from primary tumor used for
initial diagnosis in 130 out of 132 cases. In two cases only the
analysis was performed on metastatic sites (liver).
PTEN expression
PTEN protein expression was evaluated by immunohistochemistry
on 3 mm FFPE tissue sections as reported [24] with some
modifications. Briefly, anti-PTEN Ab4 (Thermo Fisher Scientific,
CA, USA) with 1:200 dilution and PTENAb2 (Neomarkers, Fremont,
Figure 6. Following evaluation of KRAS status in individual tumors, enhancement of predictability of clinical benefit may derive
from assessment of the status of BRAF, PIK3CA and PTEN, as simulated here based on analyses of subgroups from the present
cohort (n=131). We propose to define as ‘‘quadruple negative’’ the mCRCs lacking alterations in KRAS, BRAF, PTEN and PIK3CA.
doi:10.1371/journal.pone.0007287.g006
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CA) with 1:50 dilution were used at the Niguarda Hospital and at the
Institute of Pathology of Locarno, respectively. PTEN protein
expression was mainly detected at cytoplasmic level, while very few
cases showed also nuclear positivity. Tumors were considered negative,
i.e. with loss of PTEN expression, when absence or reduction of
immunostaining was seen in more than 50% of cells as compared with
internal controls (i.e. vascular endothelial cells and nerves). Normal
endometrium was used as external positive control. The evaluations
were performed by two independent pathologists without knowledge of
clinical data or results of molecular analyses.
Mutational analysis of KRAS, BRAF and PIK3CA in tumor
samples
We searched for KRAS (exon 2), for BRAF (exon 15) and for PIK3CA
(exons 9 and 20) mutations. KRAS exon 2 includes codons 12 and 13,
BRAF exon 15 includes codon 600, PIK3CA exon 9 includes codons
542 and 545 and PIK3CA exon 20 includes codon 1047, where the
large majority of mutations occur in these genes [29]. The list of
primers used for mutational analysis is available from the authors upon
request. All samples were subjected to automated sequencing by ABI
PRISM 3730 (Applied Biosystems, Foster City, CA, USA). All mutated
cases were confirmed twice with independent PCR reactions.
Statistical analyses
All data were analyzed with the suitable descriptive statistical
methods, after checking their distributions by means of the Shapiro-
Wilk test. Cross-tabulations of qualitative variables were analyzed
with the Fisher’s exact test, while comparisons between continuous
variables were carried out with Student’s t or Mann-Whitney U
tests. Logistic regression with Wald’s test, and exact logistic
regression (dealing with one-way causation, such as the case where
all patients in a group show a positive or negative outcome), with
exact p-value (as the probability of observing a more extreme value
with respect to sufficient statistics for a given regression parameter)
were used to assess univariate and multivariate analysis with binary
endpoint. The survival analysis was performed with the Kaplan-
Meier survivor function followed by logrank test, and with the Cox
model; proportional hazard assumption was checked using the
Schoenfeld residuals. Statistical significance was assumed for
p,0.05. All the statistical analyses were done using Stata/SE 10.1
(the StataCorp, College Station,TX-USA).
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